Rhythm Pharmaceuticals, Inc. RYTM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 89.4%-0.2pp | 89.7%0.0pp | 89.4%+0.8pp | 89.2%+0.4pp | 89.6%+1.2pp | |
| Operating margin | -90.9%+35.2pp | -101.2%+103pp | -106.8%+129pp | -113.5%+147pp | -126.1%+169pp | |
| Net margin | -93.3%+29.9pp | -103.6%+96.7pp | -110.3%+120pp | -117.1%+138pp | -123.3%+175pp | |
| Returns | ||||||
| Return on equity | -285.8%+133pp | -244.5%+27.7pp | -240.4%+7.8pp | —— | -419%-224pp | |
| Return on invested capital | -197.9%+770pp | -157.9%+43.7pp | —— | —— | -967.9%-519pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.2×+0.9× | 4.4×+1.2× | 4.7×+1.3× | 2.8×-3.7× | 3.3×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×-5.1× | 0.8×-4.4× | 0.8×+0.4× | —— | 6×+6.0× | |
| Per Share | ||||||
| Book value per share | $1.81+502% | $2.14+501% | $2.25+1,126% | -$0.19-129% | $0.30-70.7% | |
| Valuation | ||||||
| Market capitalization | $5.94B+77.3% | $7.14B+108% | $6.71B+110% | $4.05B+64.0% | $3.35B+28.5% | |
| Price / sales | 27.3×+2.9× | 37.6×+11.2× | 38.5×+10.1× | 25.9×+1.7× | 24.5×-3.9× | |
| Price / book | 48.3×-128× | 51.4×-107× | 45.1×-240× | —— | 176.8×+134× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Rhythm Pharmaceuticals, Inc. (RYTM) runs a 89.4% gross margin and a -90.9% operating margin, with a -93.3% net margin.
- Where do Rhythm Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Rhythm Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
